The prevalence of type 2 diabetes mellitus (T2DM), which is associated with cardiovascular morbidity and mortality, is increasing worldwide. Although there have been advances in diabetes treatments that reduce microvascular complications (nephropathy, neuropathy, retinopathy), many clinical studies have found that conventional oral hypoglycemic agents and glucose control alone failed to reduce cardiovascular disease. Thus, incretin-based therapies including glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2Is) represent a new area of research, and may serve as novel therapeutics for treating hyperglycemia and modifying other cardiovascular risk factors. Recently, it has been confirmed that several drugs in these classes, including canagliflozin, empagliflozin, semaglutide, and liraglutide, are safe and possess cardioprotective effects. We review the most recent cardiovascular outcome trials on GLP-1RAs and SGLT-2Is, and discuss their implications for treating patients with T2DM in terms of protective effects against cardiovascular disease.

Citations

Citations to this article as recorded by  

• Switch to gliflozins and biventricular function improvement in patients with chronic heart failure and diabetes mellitus
  Michele Correale, Pietro Mazzeo, Martino Fortunato, Matteo Paradiso, Andrea Furore, Angela I. Fanizzi, Lucia Tricarico, Giuseppe Pastore, Simona Alfieri, Natale D. Brunetti, Olga Lamacchia
  Clinical Physiology and Functional Imaging.2024; 44(1): 112.     CrossRef
• Association between underweight and risk of heart failure in diabetes patients
  Tae Kyung Yoo, Kyung‐Do Han, Eun‐Jung Rhee, Won‐Young Lee
  Journal of Cachexia, Sarcopenia and Muscle.2024; 15(2): 671.     CrossRef
• Paradigm Shift in Management of Hyperglycemia in Patients with Type 2 Diabetes: Glucocentric versus Organ Protection
  Jong Chul Won
  The Journal of Korean Diabetes.2023; 24(2): 59.     CrossRef
• Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies
  Braden Millar, Monica de Gaetano
  Frontiers in Pharmacology.2023;[Epub]     CrossRef
• Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study
  Paolo Basile, Andrea Igoren Guaricci, Giuseppina Piazzolla, Sara Volpe, Alfredo Vozza, Marina Benedetto, Maria Cristina Carella, Daniela Santoro, Francesco Monitillo, Andrea Baggiano, Saima Mushtaq, Laura Fusini, Fabio Fazzari, Cinzia Forleo, Nunziata Rib
  Journal of Clinical Medicine.2023; 12(4): 1586.     CrossRef
• Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study
  Michele Correale, Elena‐Laura Antohi, Riccardo M. Inciardi, Pietro Mazzeo, Stefano Coiro, Shiro Ishihara, Renata Petroni, Francesco Monitillo, Marta Leone, Marco Triggiani, Chaudhry M.S. Sarwar, Hans‐Dirk Dungen, Khawaja M. Talha, Natale D. Brunetti, Jave
  ESC Heart Failure.2023; 10(3): 2066.     CrossRef
• Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up
  Elena-Daniela Grigorescu, Cristina-Mihaela Lăcătușu, Mariana Floria, Georgiana-Diana Cazac, Alina Onofriescu, Livia-Amira Sauciuc, Alexandr Ceasovschih, Ioana Crețu, Bogdan-Mircea Mihai, Laurențiu Șorodoc
  Diagnostics.2023; 13(17): 2817.     CrossRef
• Role of moesin in the effect of glucagon-like peptide-1 on advanced glycation end products-induced endothelial barrier dysfunction
  Yan Liu, Zhenzhen Chen, Lei Liu, Haitao Tang, Huaqing Zhu, Songtao Tang
  Cellular Signalling.2022; 90: 110193.     CrossRef
• Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
  Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
  Diabetes Therapy.2021; 12(1): 171.     CrossRef
• Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention
  Jung Ha Park, Ju Young Kim, Jong Han Choi, Hye Soon Park, Hyun-Young Shin, Jae Min Lee, Jin-Wook Kim, Hae-Jin Ko, Suk Chon, Bu Kyung Kim, Chul Sik Kim, Soo Lim
  International Journal of Obesity.2021; 45(4): 776.     CrossRef
• Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
  Shruti S Joshi, Trisha Singh, David E Newby, Jagdeep Singh
  Heart.2021; 107(13): 1032.     CrossRef
• Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
  Da-Peng Zhang, Li Xu, Le-Feng Wang, Hong-Jiang Wang, Feng Jiang
  Cardiovascular Diabetology.2020;[Epub]     CrossRef
• Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
  Kyung-Soo Kim, Byung-Wan Lee
  Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
• Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
  Kohei Kaku, Koichi Kisanuki, Mari Shibata, Takashi Oohira
  Drug Safety.2019; 42(11): 1311.     CrossRef